- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| PHARMA KONTOR Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 21,255 | -0,12 % | Where Will Pfizer Be in 5 Years? | ||
| NOVARTIS | 118,22 | +0,03 % | Aktien Europa: Gewinne - EuroStoxx mit Kurs auf Jahreshoch | PARIS/LONDON/ZÜRICH (dpa-AFX) - Die europäischen Börsen haben am Dienstag leichte Gewinne verzeichnet. Damit knüpften die Märkte kurz vor dem Jahresende an die Stärke im Jahresverlauf an. Der EuroStoxx... ► Artikel lesen | |
| ROCHE | 354,30 | +0,10 % | Royalty Pharma plc: Royalty Pharma Acquires Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones | NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired the final portion of PTC Therapeutics' remaining royalty on Roche's Evrysdi for $240... ► Artikel lesen | |
| TEVA | 26,500 | -1,49 % | $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth This Much Today | ||
| BIOTEST | 31,600 | +0,64 % | Biotest erhält FDA-Zulassung | Summary: FDA lässt Fibrinogen-Produkt für den US-Markt zu Biotest entwickelt und produziert, Grifols vermarktet Markteinführung für 2026 geplant Pipeline gewinnt strategisch an Gewicht Biotest hat einen... ► Artikel lesen | |
| NEURIZON THERAPEUTICS | 0,044 | -20,72 % | NEURIZON THERAPEUTICS LIMITED: Application for quotation of securities - NUZ | ||
| SYNTARA | 0,012 | +4,35 % | XFRA UUDA: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| HARROW | 49,000 | 0,00 % | Harrow, Inc.: Harrow Health, Inc. Announces Closing of Acquisition of Melt Pharmaceuticals | NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 6,450 | +1,10 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Broadens Patent Estate for Anaphylm | New patents extend protection for Anaphylm into 2037Anaphylm (dibutepinephrine) Sublingual Film, if approved by the FDA, will be the first and only oral medication for the rescue treatment of severe... ► Artikel lesen | |
| LB PHARMACEUTICALS | 22,250 | +3,49 % | LB Pharmaceuticals Inc: LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer | NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 16,910 | +0,71 % | Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution) | - NDA assigned a Target Action Date of February 25, 2026 -- Product has patent protection through 2044 - DEER PARK, Ill., July 08, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 78,26 | +3,18 % | H.C. Wainwright reiterates Buy rating on Bright Minds stock with $115 target | ||
| MILESTONE PHARMACEUTICALS | 2,020 | 0,00 % | Milestone Pharmaceuticals Inc.: Milestone Receives FDA Approval of CARDAMYST (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) | First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythmFDA approval in PSVT enables... ► Artikel lesen | |
| LIPOCINE | 8,030 | +22,22 % | Lipocine Inc.: Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone | Second Drug Safety Monitoring Board (DSMB) meeting update planned for mid-January 2026
Topline results on track for the second quarter of 2026
SALT LAKE CITY... ► Artikel lesen | |
| INTERCURE | 0,910 | -8,36 % | Intercure Ltd. - 6-K, Report of foreign issuer |
PHARMA KONTOR AG gehört der Branche Pharma an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHARMA KONTOR AG finden Sie auf Wallstreet Online.